Publications may either be freely available or require a fee to view (or access) on the journal’s website.
Clinicians and patients have been uncertain about the optimal time to start biologics for polyarticular juvenile idiopathic arthritis (pJIA). However, results from this PCORI-funded study, published in Arthritis & Rheumatology, provide useful new evidence about first-line treatment options for this disease. Researchers compared the effectiveness of three treatment approaches among 400 children with pJIA. The approaches included starting patients on a non-biologic disease-modifying antirheumatic drug (DMARD) only, starting patients with a DMARD and a biologic medication, and starting patients with a biologic only. After one year, the approaches did not differ significantly in achieving clinically inactive disease without the use of glucorticoids, and patients reported decreased pain interference levels and increased mobility with all three approaches.